<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563769</url>
  </required_header>
  <id_info>
    <org_study_id>23222</org_study_id>
    <secondary_id>1U54DA039002-01</secondary_id>
    <nct_id>NCT02563769</nct_id>
  </id_info>
  <brief_title>Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study</brief_title>
  <official_title>Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Clavulanic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if it is safe to use the study drug,
      clavulanic acid, in combination with cocaine. In this study, subjects will receive
      intravenous (i.v.) cocaine and the study drug, clavulanic acid. The safety of clavulanic acid
      is being studied so future studies can be done to find out if this drug is helpful in
      treating cocaine dependence. Currently, there is no available medication treatment for
      cocaine dependence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Occurrence of Adverse Events (AEs) as a Measure of Safety and Tolerability of Clavulanic Acid (CLAV)</measure>
    <time_frame>6 Days (Study Days 1, 2, 3, 4, 5, 10)</time_frame>
    <description>Safety and toleration as assessed by the rates of occurrence of adverse events across the three study periods within each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Cardiovascular Responses as a Measure of Safety and Tolerability of Clavulanic Acid (CLAV)</measure>
    <time_frame>5 Days (Study Days 1, 2, 3, 4, 5)</time_frame>
    <description>Cardiovascular responses induced by cocaine infusion will be compared to cardiovascular response measurements before the cocaine infusion to assess change. Cardiovascular changes after infusion given after CLAV (250 mg, 500 mg) will be compared to those without CLAV. We will compare the distribution of Area Under Curve (AUC) summaries of the within-period repeated measures of changes in vital signs (heart rate, systolic blood pressure, diastolic blood pressure) across the three-periods within each person.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter of Cocaine and its major metabolite, benzoylecgonine (BE): Maximum Observed Concentration (Cmax)</measure>
    <time_frame>4 Days (Study Days 2, 3, 4, 5)</time_frame>
    <description>PK parameters of cocaine alone will be compared statistically with parameters when both cocaine and clavulanic acid (250 mg, 500 mg) are present.
Cmax = Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter of Clavulanic Acid (CLAV): Maximum Observed Concentration (Cmax)</measure>
    <time_frame>4 Days (Study Days 2, 3, 4, 5)</time_frame>
    <description>PK parameters of clavulanic acid alone will be compared statistically at both doses of clavulanic acid (250 mg, 500 mg).
Cmax = Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of Cocaine and Clavulanic Acid</measure>
    <time_frame>4 Days (Study Days 1, 2, 3, 4, 5)</time_frame>
    <description>Pupil Diameter (over time) after cocaine infusion alone (with placebo) will be compared with pupil diameter (over time) after cocaine infusion with clavulanic acid at both doses (250 mg, 500 mg).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Cocaine Addiction</condition>
  <condition>Cocaine Abuse</condition>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo; Day #5 Clavulanic Acid 750 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg; Day #5 Clavulanic Acid 750 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg; Day #5 Clavulanic Acid 750 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clavulanic acid</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_label>Treatment Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous cocaine</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_label>Treatment Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_label>Treatment Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-5 criteria for cocaine use disorder, moderate to severe.

          -  Be a non-treatment seeking cocaine user.

          -  If female and of childbearing potential, must have a negative pregnancy test within 48
             hours of beginning the study and be willing to use acceptable contraception or be
             abstinent for 14 days prior to study, through the entire study and 30 days after study
             participation.

        Exclusion Criteria:

          -  Be seeking treatment for substance abuse.

        (For full inclusion/exclusion criteria or for more information, please contact the site
        directly.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle M. Kampman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>U54 Principal Investigator - University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary F. Morrison, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. I Walters, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary F. Morrison, M.D., M.S.</last_name>
    <phone>215-707-8688</phone>
    <email>Mary.Morrison@tuhs.temple.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric M Cunningham, B.S.</last_name>
    <phone>215 707 7915</phone>
    <email>eric.cunningham@tuhs.temple.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Temple University Hospital - Episcopal Campus</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary F. Morrison, M.D., M.S.</last_name>
      <phone>215-707-8688</phone>
      <email>Mary.Morrison@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eric M Cunningham, B.A.</last_name>
      <phone>215-707-7915</phone>
      <email>eric.cunningham@tuhs.temple.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary F. Morrison, M.D., M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Ingre Walters, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Targets. 2008 Nov;7(5):482-91. Review.</citation>
    <PMID>19128205</PMID>
  </reference>
  <reference>
    <citation>Rasmussen BA, Baron DA, Kim JK, Unterwald EM, Rawls SM. β-Lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of rats. Amino Acids. 2011 Feb;40(2):761-4. doi: 10.1007/s00726-010-0589-0. Epub 2010 Apr 13.</citation>
    <PMID>20383795</PMID>
  </reference>
  <reference>
    <citation>Ward SJ, Rasmussen BA, Corley G, Henry C, Kim JK, Walker EA, Rawls SM. Beta-lactam antibiotic decreases acquisition of and motivation to respond for cocaine, but not sweet food, in C57Bl/6 mice. Behav Pharmacol. 2011 Aug;22(4):370-3. doi: 10.1097/FBP.0b013e3283473c10.</citation>
    <PMID>21543969</PMID>
  </reference>
  <reference>
    <citation>Kovalevich J, Corley G, Yen W, Rawls SM, Langford D. Cocaine-induced loss of white matter proteins in the adult mouse nucleus accumbens is attenuated by administration of a β-lactam antibiotic during cocaine withdrawal. Am J Pathol. 2012 Dec;181(6):1921-7. doi: 10.1016/j.ajpath.2012.08.013. Epub 2012 Sep 29.</citation>
    <PMID>23031254</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Clavulanic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

